Julie Laurin
Corporate Officer/Principal chez Alethia Biotherapeutics, Inc.
Postes actifs de Julie Laurin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - | - |
Historique de carrière de Julie Laurin
Anciens postes connus de Julie Laurin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DAVIDSTEA INC. | Corporate Officer/Principal | 01/06/2019 | 01/05/2020 |
| BELLUS HEALTH | Corporate Officer/Principal | - | - |
Formation de Julie Laurin
| University of Montréal | Doctorate Degree |
Statistiques
Internationale
| Canada | 5 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
| Consumer Non-Durables | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DAVIDSTEA INC. | Consumer Non-Durables |
| Entreprise privées | 2 |
|---|---|
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Bourse
- Insiders
- Julie Laurin
- Expérience
